Sotac Pharmaceuticals
SOTAC NSE
Sotac Pharmaceuticals
HealthcareNSE: SOTAC Pharmaceuticals & Biotechnology
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹99.51 Cr
Volatility
Moderate
P/E Ratio
17.3
EBITDA
₹17.88 Cr
Return on Equity
15.88%
Debt to Equity
0.64
Book Value
₹53.28
52W High
₹139.65
52W Low
₹86
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has delivered good profit growth of 34.7% CAGR over last 5 years
Weaknesses
1- Company has a low return on equity of 13.0% over last 3 years.
Growth Rate
Revenue Growth
0.34% lower than
3Y
Net Income Growth
-28.82% lower than
3Y
Cash Flow Change
73.07% higher than
3Y
ROE
119% higher than
3Y
ROCE
105% higher than
3Y
EBITDA Margin (Avg.)
1.27% lower than
3Y
Quarterly Results
| Particulars | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 38 | 52 | 52 | 53 | 47 | 37 | 60 |
| Expenses | 36 | 34 | 47 | 48 | 48 | 35 | 33 | 50 |
| Operating Profit | 3 | 4 | 4 | 4 | 4 | 12 | 4 | 10 |
| OPM % | 9% | 10% | 9% | 8% | 8% | 26% | 10% | 17% |
| Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 |
| PBT | 2 | 2 | 2 | 2 | 3 | 9 | 3 | 5 |
| Tax % | 49% | 34% | 45% | -34% | 30% | 13% | 23% | 31% |
| Net Profit | 2 | 1 | 2 | 3 | 2 | 6 | 2 | 3 |
| EPS in Rs | 6.78 | 1.64 | 1.57 | 2.31 | 1.73 | 5.53 | 2.22 | 3 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 29 | 49 | 77 | 104 | 97 | 101 |
| Expenses | 27 | 47 | 70 | 95 | 83 | 83 |
| Operating Profit | 2 | 1 | 7 | 9 | 14 | 18 |
| OPM % | 7% | 3% | 10% | 8% | 14% | 18% |
| Other Income | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 3 | 2 | 3 | 4 | 5 |
| PBT | 0 | -2 | 4 | 4 | 11 | 9 |
| Tax % | 75% | 15% | 42% | 10% | 17% | 28% |
| Net Profit | 0 | -2 | 2 | 4 | 9 | 6 |
| EPS in Rs | 0.39 | -10.3 | 3.58 | 3.87 | 7.27 | 5.22 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 4% |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 42 | 48 |
| Borrowings | 13 | 17 | 22 | 25 | 44 | 38 |
| Other Liabilities | 14 | 15 | 32 | 35 | 27 | 37 |
| Total Liabilities | 30 | 35 | 74 | 105 | 124 | 133 |
| Fixed Assets | 16 | 17 | 26 | 36 | 49 | 50 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 2 |
| Investments | 0 | 0 | 0 | 2 | 4 | 3 |
| Other Assets | 14 | 18 | 48 | 63 | 72 | 79 |
| Total Assets | 30 | 35 | 74 | 105 | 124 | 133 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 8 | -16 | -4 | 17 |
| Investing | -12 | -3 | -12 | -20 | -14 | -7 |
| Financing | 11 | 3 | 13 | 29 | 16 | -10 |
| Net Cash Flow | 0 | 0 | 10 | -6 | -2 | 0 |
| Free Cash Flow | -10 | -3 | 0 | -34 | -16 | 9 |
| CFO/OP | 17 | 8 | 134 | -168 | -26 | 106 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | 92 | 128 | 119 |
| Inventory Days | 40 | 45 | 87 | 83 | 108 | 153 |
| Days Payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash Conversion Cycle | -66 | -32 | -5 | 43 | 136 | 118 |
| Working Capital Days | -79 | -44 | -40 | 47 | 63 | 65 |
| ROCE % | — | -5% | — | 10% | 15% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sotac Pharmaceuticals insights
54 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Shareholders meeting
8 Sep - 11th AGM on Sept 30, 2026; proposes ₹0.20 dividend and ₹85 crore related party transactions. 8 Sep - 11th AGM on Sept 30, 2026; proposes ₹0.20 dividend and ₹85 crore related party transactions.
2
Record Date
8 Sep - AGM on September 30, 2026; record date September 23, 2026 for Rs 0.20 final dividend. 8 Sep - AGM on September 30, 2026; record date September 23, 2026 for Rs 0.20 final dividend.
3
General Updates
8 Sep - 11th AGM on September 30, 2026; annual report link and e-voting schedule shared. 8 Sep - 11th AGM on September 30, 2026; annual report link and e-voting schedule shared.
4
Copy of Newspaper Publication
8 Sep - 11th AGM notice published; AGM on September 30, 2026, with annual report and e-voting details. 8 Sep - 11th AGM notice published; AGM on September 30, 2026, with annual report and e-voting details.
5
Outcome of Board Meeting
7 Sep - Board approved AGM on Sept 30, 2026, Rs.0.20 dividend record date Sept 23, and cost auditor appointment. 7 Sep - Board approved AGM on Sept 30, 2026, Rs.0.20 dividend record date Sept 23, and cost auditor appointment.
Frequently Asked Questions about Sotac Pharmaceuticals
What does Sotac Pharmaceuticals Ltd do?
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
Where is Sotac Pharmaceuticals Ltd (SOTAC) listed?
Sotac Pharmaceuticals Ltd trades as SOTAC on the NSE.
Which sector does Sotac Pharmaceuticals Ltd belong to?
Sotac Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd has a market capitalisation of ₹99.51 Cr, which places it in the Small Cap band.
What is the PE ratio of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd trades at a PE ratio of 17.30, against a book value of ₹53.28 per share.
What is the 52-week high and low of Sotac Pharmaceuticals Ltd?
Over the last 52 weeks Sotac Pharmaceuticals Ltd has traded between ₹86 and ₹139.65.
Does Sotac Pharmaceuticals Ltd pay dividends?
Sotac Pharmaceuticals Ltd has a dividend yield of 0.11%.
What is the Return on Equity (ROE) of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd reported a return on equity of 15.88%. Its debt-to-equity ratio is 0.64.
Company Information
Incorporated in 2015, Sotac Pharmaceuticals Ltd manufactures and sells a wide range of pharmaceutical products[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SOTAC.md for Sotac Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.